Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabinoids for Traumatic Brain Injury
NCT05632627Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Apr 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cannabidiol in traumatic brain injury (TBI) (3 arms), sponsored by University of Colorado Denver. Primary endpoints: Change in Neuropsychiatric Symptoms at 12 weeks and Change in Cognition at 12 weeks. Started Apr 2023; status: completed.
02
Drugs
cannabidiol
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05632627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632627.